Ipsen Delivers Strong Sales Growth Of 18.8%1 In The First Half Of 2017 And Upgrades Its Guidance For Full Year 2017

PARIS--(BUSINESS WIRE)--Regulatory News:

Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced financial results for the first half of 2017.

H1 2017 Highlights

• Strong operating performance of 18.8%¹ Group sales growth and Core Operating Income margin improvement by 1.2 points to 26.2% of sales
• Specialty Care sales growth of 23.1%¹ reflects continued Somatuline^® momentum and includes contribution of key new products Cabometyx^® and Onivyde^®
• Consumer Healthcare sales growth of 1.3%¹ including contribution of newly acquired products
• Upgraded full year 2017 guidance of Specialty Care sales growth greater than 24.0%¹, slight growth¹ of Consumer Healthcare sales, and Core Operating Income margin greater than 25.0% of sales